Israeli life science research company ProFuse Technology has launched ProFuse-B8, a spontaneously immortalised bovine myoblast cell line available for licensing.
This innovative development marks a significant milestone in the cell-based meat industry, with the potential to boost the efficient cultivation of protein-rich muscle tissue.
ProFuse-B8 has been extensively researched and tested over the last two years. The cell line provides cell-based meat producers with a “stable and robust” foundation for the development of scalable, repeatable and cost-competitive production processes.
Notably, B8 achieves these benefits without using genetic modification technology – positively impacting consumer preferences and acceptance.
In January, the company unveiled ProFuse-S1, a media supplement engineered to accelerate and enhance skeletal muscle research across various sectors including cell-based meat.
When B8 is integrated with ProFuse-S1 muscle differentiation media, supplement muscle tissue production is accelerated, which offers increased efficiency within shorter production times.
ProFuse Technology is also working to develop additional muscle production-optimised cell lines tailored for the cultivation of chicken, pork, lamb and fish.
Tamar Eigler-Hirsh, CTO and co-founder at ProFuse Technology, said: "We are thrilled to introduce ProFuse-B8 as a transformative solution for the cultivated meat industry. Our dedication to innovation and productivity is evident in the development of this breakthrough cell line, and we are confident it will shape the future of cell-based protein production."